Jeffery C. Ward, MD, President The Washington State Medical Oncology Society (WSMOS) was formed in 1993. WSMOS membership represents a majority of the medical cancer specialists treating cancer patients in Washington. Our mission is to provide advocacy for cancer patients and to promote standards of excellence for high-quality cancer care. The primary interests of the Society are: To identify and work to improve oncology practice issues that adversely affect patient access to cancer care To act as a patient advocate to assure that patients have access to the best available care To support and encourage clinical research against cancer In order to carry out these interests, some of the goals for the Society include: Affect legislation and public policy relative to patient access to cancer care Act as a resource on the "accepted medical practices" associated with cancer care Provide a forum for education of our members on current technologies and their role as accepted medical practices Provide communications to our members and others on issues affecting patient access to cancer care and the practice of oncology

Sanofi-aventis Announces Jevtana Approval Sanofi-aventis is pleased to announce that on June 17, 2010, the US Food and Drug Administration (FDA) approved Jevtana® (cabazitaxel) Injection. In addition, as of July 19, 2010, Jevtana is now commercially available. Product related billing information is provided below: National Drug Codes (NDCs) NDC Assigned:    00024-5824-11        Packaging: Carton of one (1) Jevtana vial & one (1) Diluent vial HCPCS Codes J9999     Not otherwise classified (NOC) antineoplastic drugs C9399    Unclassified drugs or biologicals For more information on Jevtana, please click here for full prescribing information, including boxed WARNING. Updated VELCADE Label Announced On January 4, 2010 Millennium announced that the FDA has approved a supplemental new drug application (sNDA) for VELCADE, which expands the label to include long-term overall survival data from the landmark VISTA trial and provides specific dosing recommendations for patients with hepatic impairment. the VISTA trial examined the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM). Click Here to read the press release, Click Here to read the Physician Announcement Letter                       This website brought to you by:   Washington State Medical Oncology Society 113 W. 7th Street Suite 205 Vancouver, Washington 98660 360.258.0443 Phone 360.695.6937 Fax wsmos@comcast.net